− Type II Variation Submission Based on the Positive HELIOS-B Phase 3 Study in which Vutrisiran Significantly Reduced the Risk of Death and Cardiovascular Events Relative to Placebo – “Today marks ...

If you or a loved one are living with hereditary ATTR amyloidosis with cardiomyopathy (hATTR-CM), you are likely well-acquainted with the challenges of heart health. You know the fatigue, the ...

This rare condition can’t be cured, but its symptoms can be treated. Take this assessment to learn what more you can do to manage the condition. Before you were diagnosed with transthyretin ...

By determining the structure of the deposits responsible for transthyretin amyloidosis through a simple skin biopsy, ...

"ATTR amyloidosis was characterized by distinct patterns of functional impairment across all disease phenotypes, attributable to multiple physiological mechanisms. Multiple CPET parameters were ...

Please provide your email address to receive an email when new articles are posted on . Vutrisiran lowered risk for death and recurrent CV events vs. placebo in patients with ATTR-CM. The results were ...

Cardiac amyloidosis (CA) is a progressive infiltrative cardiomyopathy resulting from the extracellular deposition of misfolded proteins, most commonly transthyretin (ATTR) or immunoglobulin light ...

Driven by accelerating diagnosis of ATTR cardiomyopathy, sustained reliance on cost-effective chemotherapy, and rapid uptake ...

After a patient safety signal and then death, the FDA in October 2025 placed holds on two of the company’s CRISPR programs ...

According to a new study published in ESC Heart Failure, nearly 1 in 5 elderly patients with a permanent cardiac pacemaker and left ventricular hypertrophy (LVH) have transthyretin amyloid ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNA interference (RNAi) therapeutics company, today announced that the Committee for Medicinal Products for ...

Please provide your email address to receive an email when new articles are posted on . Alnylam announced positive top-line results of its phase 3 trial of vutrisiran for the treatment of ATTR ...